Companies from Johnson & Johnson to Eli Lilly, Amazon and Nvidia are announcing health-related deals at the JPMorgan Health ...
Lilly revised its revenue guidance down 5%, to $13.5 billion, missing consensus of $14 billion by $500 million. But the guidance still represents a 45% increase from the same quarter in 2023. Lilly ...
Stocks got a boost from a report showing inflation at the U.S. wholesale level wasn’t as high last month as economists ...
Eli Lilly & Co. reported preliminary fourth-quarter revenue that missed analyst estimates on lower-than-expected sales of its ...
"LCCI Hyderabad will focus on scaling up Lilly's innovation and efficiency by unlocking new technological advancements ... executive vice president, Eli Lilly."LCCI Hyderabad will bring together ...
Eli Lilly’s market capitalisation was just over $750bn as of early Friday afternoon in New York. It is expected to generate about $46bn in sales this year, much of this from Mounjaro and Zepbound.
For more audio journalism and storytelling, download New York Times Audio ... David Ricks, the chair and chief executive of Eli Lilly, and Dr. Fatima Cody Stanford, obesity medicine physician ...
Hyderabad: The queue of global pharma giants wanting to make Hyderabad their new home ... the city is now learnt to be on the radar of pharma giants such as Eli Lilly, GSK, and Merck.
An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City. The Food and Drug Administration approved the drug as a treatment for people with moderate to severe ...
An Eli Lilly & Co. Zepbound injection pen arranged in the Brooklyn borough of New York, March 28, 2024. (Shelby Knowles/Bloomberg via Getty Images) Obstructive sleep apnea isn’t just an ...
In a study, people who took Zepbound had fewer breathing interruptions. The FDA has expanded the approval of Eli Lilly’s obesity medication Zepbound to include treating moderate to severe ...